Proteomics and phospho-proteomics profiling of the co-formulation of type i and ii interferons, heberferon, in the glioblastoma-derived cell line u-87 mg

HIGHLIGHTS

• who: Dania Vu00e1zquez-Blomquist and collaborators from the Du00e9partement de Neurosciences, Universitu00e9 de Montru00e9al, Montru00e9al, QC H L, Canada have published the article: Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG, in the Journal: Cells 2022, 4068 of /2022/
• what: It has antiproliferative effects over glioblastoma multiform (GBM) clones and cultured cell lines including U-87 Here the authors report the first label-free quantitative proteomic and phospho-proteomic analyses to evaluate changes induced by after 72 h . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.